Back to Search
Start Over
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
- Source :
- The Lancet Respiratory Medicine; October 2022, Vol. 10 Issue: 10 p972-984, 13p
- Publication Year :
- 2022
-
Abstract
- Tixagevimab–cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab–cilgavimab versus placebo, in patients receiving remdesivir and other standard care.
Details
- Language :
- English
- ISSN :
- 22132600 and 22132619
- Volume :
- 10
- Issue :
- 10
- Database :
- Supplemental Index
- Journal :
- The Lancet Respiratory Medicine
- Publication Type :
- Periodical
- Accession number :
- ejs62035431
- Full Text :
- https://doi.org/10.1016/S2213-2600(22)00215-6